Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2001 Nov-Dec;7(6):933–944. doi: 10.3201/eid0706.010604

Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

J A Jernigan 1, D S Stephens 1, D A Ashford 1, C Omenaca 1, M S Topiel 1, M Galbraith 1, M Tapper 1, T L Fisk 1, S Zaki 1, T Popovic 1, R F Meyer 1, C P Quinn 1, S A Harper 1, S K Fridkin 1, J J Sejvar 1, C W Shepard 1, M McConnell 1, J Guarner 1, W J Shieh 1, J M Malecki 1, J L Gerberding 1, J M Hughes 1, B A Perkins 1; Anthrax Bioterrorism Investigation Team1
PMCID: PMC2631903  PMID: 11747719

Abstract

From October 4 to November 2, 2001, the first 10 confirmed cases of inhalational anthrax caused by intentional release of Bacillus anthracis were identified in the United States. Epidemiologic investigation indicated that the outbreak, in the District of Columbia, Florida, New Jersey, and New York, resulted from intentional delivery of B. anthracis spores through mailed letters or packages. We describe the clinical presentation and course of these cases of bioterrorism-related inhalational anthrax. The median age of patients was 56 years (range 43 to 73 years), 70% were male, and except for one, all were known or believed to have processed, handled, or received letters containing B. anthracis spores. The median incubation period from the time of exposure to onset of symptoms, when known (n=6), was 4 days (range 4 to 6 days). Symptoms at initial presentation included fever or chills (n=10), sweats (n=7), fatigue or malaise (n=10), minimal or nonproductive cough (n=9), dyspnea (n=8), and nausea or vomiting (n=9). The median white blood cell count was 9.8 X 10(3)/mm(3) (range 7.5 to 13.3), often with increased neutrophils and band forms. Nine patients had elevated serum transaminase levels, and six were hypoxic. All 10 patients had abnormal chest X-rays; abnormalities included infiltrates (n=7), pleural effusion (n=8), and mediastinal widening (seven patients). Computed tomography of the chest was performed on eight patients, and mediastinal lymphadenopathy was present in seven. With multidrug antibiotic regimens and supportive care, survival of patients (60%) was markedly higher (<15%) than previously reported.

Full Text

The Full Text of this article is available as a PDF (316.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALBRINK W. S., BROOKS S. M., BIRON R. E., KOPEL M. Human inhalation anthrax. A report of three fatal cases. Am J Pathol. 1960 Apr;36:457–471. [PMC free article] [PubMed] [Google Scholar]
  2. ALBRINK W. S., GOODLOW R. J. Experimental inhalation anthrax in the chimpanzee. Am J Pathol. 1959 Sep-Oct;35:1055–1065. [PMC free article] [PubMed] [Google Scholar]
  3. Abramova F. A., Grinberg L. M., Yampolskaya O. V., Walker D. H. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2291–2294. doi: 10.1073/pnas.90.6.2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BRACHMAN P. S., PLOTKIN S. A., BUMFORD F. H., ATCHISON M. M. An epidemic of inhalation anthrax: the first in the twentieth century. II. Epidemiology. Am J Hyg. 1960 Jul;72:6–23. doi: 10.1093/oxfordjournals.aje.a120135. [DOI] [PubMed] [Google Scholar]
  5. Brachman P. S. Inhalation anthrax. Ann N Y Acad Sci. 1980;353:83–93. doi: 10.1111/j.1749-6632.1980.tb18910.x. [DOI] [PubMed] [Google Scholar]
  6. Centers for Disease Control and Prevention (CDC) Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep. 2001 Oct 19;50(41):889–893. [PubMed] [Google Scholar]
  7. Centers for Disease Control and Prevention (CDC) Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001 Nov 2;50(43):941–948. [PubMed] [Google Scholar]
  8. Centers for Disease Control and Prevention (CDC) Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001 Oct 26;50(42):909–919. [PubMed] [Google Scholar]
  9. Dixon T. C., Meselson M., Guillemin J., Hanna P. C. Anthrax. N Engl J Med. 1999 Sep 9;341(11):815–826. doi: 10.1056/NEJM199909093411107. [DOI] [PubMed] [Google Scholar]
  10. GOLD H. Anthrax; a report of one hundred seventeen cases. AMA Arch Intern Med. 1955 Sep;96(3):387–396. doi: 10.1001/archinte.1955.00250140109012. [DOI] [PubMed] [Google Scholar]
  11. LaForce F. M., Bumford F. H., Feeley J. C., Stokes S. L., Snow D. B. Epidemiologic study of a fatal case of inhalation anthrax. Arch Environ Health. 1969 May;18(5):798–805. doi: 10.1080/00039896.1969.10665490. [DOI] [PubMed] [Google Scholar]
  12. Laforce F. M. Woolsorters' disease in England. Bull N Y Acad Med. 1978 Nov;54(10):956–963. [PMC free article] [PubMed] [Google Scholar]
  13. Meselson M., Guillemin J., Hugh-Jones M., Langmuir A., Popova I., Shelokov A., Yampolskaya O. The Sverdlovsk anthrax outbreak of 1979. Science. 1994 Nov 18;266(5188):1202–1208. doi: 10.1126/science.7973702. [DOI] [PubMed] [Google Scholar]
  14. PLOTKIN S. A., BRACHMAN P. S., UTELL M., BUMFORD F. H., ATCHISON M. M. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med. 1960 Dec;29:992–1001. doi: 10.1016/0002-9343(60)90079-6. [DOI] [PubMed] [Google Scholar]
  15. Suffin S. C., Carnes W. H., Kaufmann A. F. Inhalation anthrax in a home craftsman. Hum Pathol. 1978 Sep;9(5):594–597. doi: 10.1016/s0046-8177(78)80140-3. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES